EGFR and non-small cell lung carcinoma: Immunotherapy is the first-line treatment of advanced-stage NSCLC patients harboring EGFR/ALK (ALK receptor tyrosine kinase) wild type with PD-L1 expression ≥ 50% and second-line treatment when PD-L1 expression ranges between 1 and 50% (7).